Menopause
News from the FDA/CDC
FDA approves vaginal insert to treat dyspareunia in menopause
It’s the first FDA-approved product containing the active ingredient prasterone, known also as DHEA. It will be marketed by Endoceutics Inc., a...
Feature
It’s not easy to identify clinical depression in menopause
Clinical depression isn’t a more severe extreme of milder depressive symptoms, but rather a distinct clinical entity, said Hadine Joffe, MD, and...
Feature
NAMS hormone therapy guidelines stress individualized treatment
The new statement, an update from the North American Menopause Society’s 2012 recommendations, gives targeted recommendations for special...
Feature
Odanacatib reduced fractures but upped stroke risk
Based on an independent analysis and verification of the risk for stroke, the drug’s sponsor, Merck, has withdrawn odanacatib from review by the...
Conference Coverage
Early menopause a risk factor for type 2 diabetes
The risk for type 2 diabetes is increased among women who went through early menopause.
Conference Coverage
Novel fractional laser eased genitourinary syndrome of menopause
DENVER
Commentary
When is it time to stop hormone therapy?
If a woman started hormone therapy in her 50s for bothersome menopausal symptoms and now she’s in her 60s, there’s a good chance that she may have...
News for Your Practice
NAMS 2016 hormone therapy position statement
Considering new data, more than 20 experts offer consensus on hormone therapy benefits and risks overall and in special populations...
Conference Coverage
Breast arterial calcifications predict atherosclerotic cardiovascular events
Longitudinal results of a prospective study of women with and without breast arterial calcifications showed that women with the calcifications...
News
Hot flashes and sleep disruption contribute independently to depression in menopause
Hot flashes and sleep disruption contribute independently to depression in menopause